TREATING
CENTRAL SLEEP APNEA
remedē News
ZOLL Respicardia Announces SelectHealth Coverage for the remedē® System in Patients with Central Sleep Apnea
Expanded insurance coverage now available in Utah, Idaho and Nevada
ZOLL Announces Approval of Next-Generation remedē System for the Treatment of Central Sleep Apnea (transvenous phrenic nerve stimulation)
The new remedē EL-X model delivers extended longevity, reduced size, and an enhanced suite of diagnostics
ZOLL Announces Five-Year Study Confirming Safety, Efficacy and Beneficial Effects of Long-Term Transvenous Phrenic Nerve Stimulation (the remedē System)
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the peer-reviewed journal Nature and Science of Sleep has published five-year results from the remedē System Post Approval Study.
ZOLL Medical Corporation acquires Respicardia, Inc.
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has acquired Respicardia, Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA).